The efficacy of carfilzomib and dexamethason (Kd-70) as once-weekly two-drug regimen: The analysis of real-world data from Poland
Advances in Clinical and Experimental Medicine · 2025
DOI: 10.17219/acem/205167 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advances in Clinical and Experimental Medicine, 2025. Verfasst von Magdalena Olszewska-Szopa und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department and Clinic of Hematology, Cellular Therapies and Internal Medicine, University Hospital in Wrocław, Wroclaw Medical University, Poland. Hauptthemen laut MEDLINE: Multiple Myeloma, Dexamethasone, Oligopeptides, Antineoplastic Combined Chemotherapy Protocols. Der Volltext ist frei zugänglich (Open Access, CC BY 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department and Clinic of Hematology, Cellular Therapies and Internal Medicine, University Hospital in Wrocław, Wroclaw Medical University, Poland.
- Department of Finance, Wroclaw University of Economics and Business, Poland.
Zitieren
APA
Olszewska-Szopa, M., Czyż, A., Węgrzyn, M., & Wróbel, T. (2025). The efficacy of carfilzomib and dexamethason (Kd-70) as once-weekly two-drug regimen: The analysis of real-world data from Poland. Advances in Clinical and Experimental Medicine. https://doi.org/10.17219/acem/205167
Vancouver
Olszewska-Szopa M, Czyż A, Węgrzyn M, Wróbel T. The efficacy of carfilzomib and dexamethason (Kd-70) as once-weekly two-drug regimen: The analysis of real-world data from Poland. Advances in Clinical and Experimental Medicine. 2025. doi:10.17219/acem/205167
BibTeX
@article{OlszewskaSzopa2025,
author = {Olszewska-Szopa, Magdalena and Czyż, Anna and Węgrzyn, Maria and Wróbel, Tomasz},
title = {The efficacy of carfilzomib and dexamethason (Kd-70) as once-weekly two-drug regimen: The analysis of real-world data from Poland},
journal = {Advances in Clinical and Experimental Medicine},
year = {2025},
doi = {10.17219/acem/205167}
}
EUVIMED